This non-promotional presentation is intended for the investor audience and contains investigational data as well as forward-looking statements; actual results may vary materially.
Note regarding forward-looking statements & non-GAAP financial measures

This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators' ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation EYLEA® ( aflibercept) Injection, Dupixent® (dupilumab), Libtayo®(cemiplimab), Praluent® (alirocumab), Kevzara® (sarilumab), Evkzeza® (evinacumab), Imhaze® (atollivimab, mavilimab, and odesilvimb-ebgn), REGEN-COV® (casirivimab and imdevimab), faslimab, garelerab, pozelimab, odronzemab, tepilimab, REGN5458, REGN5713-5714-5715, REGN1908-1909, Regeneron’s and its collaborators’ other oncology programs (including its costimulatory bispecific portfolio), Regeneron’s and its collaborators’ earlier-stage programs, and the use of human collaborators Regeneron's research programs; safety issues resulting from the administration of Regeneron's Products and Regeneron Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including without limitation those listed above; the likelihood and timing of achieving any of the anticipated milestones described in this presentation; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron’s Products and Regeneron’s Product Candidates; the availability and extent of reimbursement of Regeneron’s Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses: the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA®, Dupixent, Praluent, and REGEN-COV®), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition; and the potential for any license or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), as well as Regeneron’s agreement with Roche relating to the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve™ in other countries) to be cancelled or terminated. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

This presentation uses total revenues excluding REGN-COV®, which is a financial measure that is not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). This and other non-GAAP financial measures are computed by excluding certain non-cash and other items from the related GAAP financial measure. Non-GAAP adjustments also include the income tax effect of reconciling items. The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company’s control, such as the Company’s stock price on the dates share-based grants are issued. Management uses non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. Additionally, non-GAAP measures provide investors with an enhanced understanding of the financial performance of the Company’s core business operations. However, there are limitations in the use of non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company’s non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measure used in this presentation is provided on slide 23.
Executing on Our Core Competencies

Driving continued growth in core franchises

Leveraging Regeneron technologies in the ongoing fight against infectious diseases

Emerging portfolio of immuno-oncology antibodies

Investing in Regeneron

Advancing a best-in-class, diversified pipeline based on in-house innovation and strategic partnerships

Investing $1.8 billion to expand our R&D capabilities and manufacturing capacity

Announced $3 billion share repurchase program in Nov 2021 ($7.8 billion shares repurchased since Nov 2019*)

Looking Ahead to the Future

30+ therapeutic candidates in various stages of clinical development

Expanding partnerships with leading companies in new technologies

* REGEN-COV is an investigational product. In January 2022, the EUA was limited by the FDA as REGEN-COV is highly unlikely to be active against the omicron variant. At this time, REGEN-COV is not authorized for use in any U.S. states, territories, and jurisdictions.

** As of December 31, 2021
Delivering Results Across the Organization

4Q 2021
Total Revenues

+17% YoY
excluding REGEN-COV*

2021
Total Revenues

+19% YoY
excluding REGEN-COV*

2021 R&D Pipeline Advancements

Positive Ph2 results for Aflibercept 8mg in wAMD

Positive Ph3 results in four potential new indications (CSU, PN, EoE, Pediatric AD 6mo-5y)

Received approval in asthma for children ages 6y-11y

Positive chemotherapy combination Ph3 results in 1L NSCLC; filed for FDA approval

Advanced CD3 & CD28 bispecifics platform

Emerging Genetics Medicines portfolio, established proof of concept for CRISPR-based therapy

* See reconciliation of non-GAAP measure on slide 23
PN – Prurigo Nodularis; EoE – Eosinophilic Esophagitis AD – Atopic Dermatitis; CSU – Chronic Spontaneous Urticaria; NSCLC – Non-Small Cell Lung Cancer; wAMD – Wet Age-Related Macular Degeneration

This slide contains investigational products not yet approved by regulatory authorities.
EYLEA®: 10 Years of Patient Impact
Extending leadership position based on efficacy and safety that has transformed millions of lives; 40+ million doses administered since launch

Developed using our proprietary Trap technology, development on aflibercept began in 2004 and became Regeneron’s second FDA-approved treatment in November 2011 as EYLEA

The #1 prescribed FDA approved anti-VEGF treatment for retinal disease
- 4Q2021 U.S. net product sales of $1.55Bn (+15% YoY)
- FY2021 U.S. net product sales of $5.79Bn (+17% YoY)

Impressive competitive durability
- ~75% share of U.S. branded category
- Breadth of indications, effective treat-and-extend dosing, with established real-world safety

Continuing to drive future growth
- Diabetic eye disease remains a significant growth opportunity
- Ph3 readouts for Aflibercept 8mg expected 2H22
  - Detailed Ph2 results in wet AMD in Feb’22 (Angiogenesis)
Dupixent®: Strong Performance Across All Approved Indications With Significant Opportunity For Sustained Growth

~$6.2Bn FY2021 global net product sales

Figures represent U.S. biologic-eligible target population; Source – Regeneron Internal Epidemiology Data
*Target population includes age groups that are not currently approved but in clinical development
CRSwNP – Chronic Rhinosinusitis with Nasal Polyps

There remains a substantial opportunity for more patients to benefit as markets remain under penetrated

Sanofi records global net product sales of Dupixent
Dupixent®: Near- and Long-Term Opportunities to Drive Growth

Estimated regulatory submission timeline for new indications

Notable Upcoming Events

- EoE, PN regulatory filing/submission
- Report Results from additional Ph3 CSU study
- Report Results from Ph3 CINDU study

Additional ~450k Addressable Population

2022e
- Eosinophilic Esophagitis
- Chronic Spontaneous Urticaria
- Prurigo Nodularis

2023e
- Bullous Pemphigoid
- Chronic Inducible Urticaria-Cold

2024+e
- Type 2 COPD
- CRSsNP
- Allergic Fungal Rhinosinusitis

Up to 4M+ Eligible Patients

Additional ~425k Addressable Population

Additional ~450k Addressable Population

Additional ~500k Addressable Population

Figures represent U.S. biologic-eligible target population; dates represent expected first FDA submission; Source – Regeneron Internal Epidemiology Data; COPD – Chronic Obstructive Pulmonary Disease; CSsNP – Chronic Sinusitis without Nasal Polyposis; CINDU – Chronic Inducible Urticaria-Cold

*Out of these eligible patients, the highest unmet need is in omalizumab non-responders (40-60% currently treated patients)
Dupixent® & Itepekimab (anti IL-33) COPD Phase 3s Underway

Two-pronged approach against uncontrolled, moderate-to-severe COPD

**Dupixent** potential to address Type 2 COPD
Achieved prespecified efficacy milestone in interim analysis of first Ph3 study
- Eosinophils ≥300/μl
- Both former and current smokers
- Two Ph3 trials ongoing
- Pivotal data expected 2023

**Itepekimab** potential also for non-Type 2 COPD
In a Ph2 study*, itepekimab demonstrated 42% exacerbation reduction vs. placebo in former smokers, regardless of Type 2 status, with no safety concerns
- No eosinophil restriction
- Focus on former smokers
- Two Ph3 trials ongoing
- Pivotal data expected 2024

<table>
<thead>
<tr>
<th>Non-Type 2</th>
<th>Type 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Itepekimab only</strong></td>
<td><strong>Dupixent or Itepekimab</strong></td>
</tr>
<tr>
<td>~600K patients</td>
<td>&gt;350K patients</td>
</tr>
</tbody>
</table>

**Current Smokers**
(30% of COPD patients*)

- Dupixent only
~150K patients

**Former Smokers**
(70% of COPD patients*)

- Itepekimab only
~600K patients

^ US, EU and Japan epidemiology, patient populations exclude never smokers (Regeneron Internal Epidemiology Data)

U.S., EU and Japan addressable patient number estimates

Dupixent and Itepekimab are developed in collaboration with Sanofi; COPD – Chronic Obstructive Pulmonary Disease

This slide contains investigational products not yet approved by regulatory authorities
Rapid Mobilization to Address COVID-19

If SARS-CoV2 remains endemic, we anticipate an enduring need for the immunocompromised

| REGEN-COV* (casirivimab and imdevimab) | 4Q21 | 2021 |
| Doses delivered* | ~1.1M | ~2.8M |
| U.S. Net Product Sales | $2.3Bn | $5.8Bn |

- **Approved** in the EU for treatment and prevention
- In Jan 2022, FDA Revised EUA for REGEN-COV due to Omicron variant – not currently authorized for use in U.S.
- **Regulatory decision** on BLA submission for treatment and prophylaxis (PDUFA 4/13/22)

Regeneron is uniquely positioned to continue to address COVID-19 and other emerging infectious disease threats in the future

**Delta (B.1.617.2):** Current REGEN-COV is active

**Omicron (B.1.1.529):** Next generation candidate active

Regulatory discussions are ongoing to establish clinical development plan

Next generation candidate could enter clinical development in the coming months

**Long-Term Potential Opportunity**

Protecting the Immunocompromised

- In the U.S. alone, millions of immunocompromised people will not adequately respond to vaccination
- Monoclonal antibody treatments can be dosed prophylactically to prevent infection and severe COVID-19

*Roche supplied a portion of these doses to Regeneron to fulfill Regeneron's agreement with the U.S. government. Roche is primarily responsible for development and distribution outside the U.S.

REGEN-COV is an investigational medicine that has authorized by FDA under an EUA for certain uses other than in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment. The development and manufacturing of REGEN-COV have been funded in part with federal funds from BARDA.
Continued Progress & Developments Across Oncology Pipeline

Regeneron positioned to enhance and extend treatment benefit across many cancer settings

**Dermato-Oncology**
- First-in-class leading treatment for advanced CSCC
-Approved in 2L+ advanced BCC
- LAG-3 combination – 1L melanoma data presented at ASCO’21
- BioNTech FixVax combination in post-PD-1 melanoma Ph2 underway

**Non-Small Cell Lung Cancer**
- Approved in 1L advanced NSCLC
- 1L NSCLC in combination with chemotherapy PDUFA 9/19/22

**Solid tumor bispecifics**

- REGN4018 (MUC16xCD3) – Dose escalation with Libtayo in ovarian cancer ongoing
- REGN5668 (MUC16xCD28) – Dose escalation with Libtayo in ovarian cancer ongoing; first patients dosed in combination with MUC16xCD3, well tolerated
- REGN5678 (PSMAxCD28) – Dose escalation with Libtayo in mCRPC ongoing
- REGN4336 (PSMAxCD3) – Enrolling
- REGN7075 (EGFRxCD28) – Dose escalation with Libtayo in advanced cancers ongoing
- REGN5093 (METxCD) – Dose expansion in MET-altered NSCLC ongoing
- REGN5093-M114 (METxCD ADC) – Now enrolling

**Heme-onc bispecifics**

- Odronextamab (CD20xCD3) – Resumed enrollment in potentially pivotal Ph2 in R/R NHL
- REGN5458 (BCMAxCD3) – Ph1 data updated at ASH’21; potentially pivotal Ph2 in dose expansion
- Both will be entering combination studies with corresponding costim (CD28) bispecifics

CSCC – Cutaneous Squamous Cell Carcinoma; BCC – Basal Cell Carcinoma; NSCLC – Non-Small Cell Lung Cancer; mCRPC - metastatic Castration-Resistant Prostate cancer; NHL – Non-Hodgkin’s lymphoma

This slide contains investigational products not yet approved by regulatory authorities
Regeneron’s Oncology Toolkit Provides Unique Combinatorial Flexibility

VelocImmune® Antibodies

Antibodies

CD3 Bispecifics

LAG3
GITR
CTLA-4

Bispecifics

CD20 Lymphoma TAA
BCMA Multiple Myeloma TAA
MUC16 Ovarian Cancer MUC16
PSMA PSMA EGFR

Costimulatory Bispecifics

New Classes of Bispecifics

Collaborations

Adicet Bio
BioNTech
Vyriad
Nykode
ISA
2seventy bio (bluebird)
Others

Libtayo is jointly developed with Sanofi.
Several agents are studied in combination with Libtayo, in addition to the combinations highlighted by boxes.

This slide contains investigational products not yet approved by regulatory authorities.
Bispecifics for Heme-Onc Malignancies: Promising Results from Maturing CD3 Programs

Combinations with costimulatory bispecifics and other agents entering clinic soon

Summary – A single, off-the-shelf bispecific, effective in both indolent and aggressive lymphomas, including patients who failed CAR-Ts

- R/R FL: ORR=90% CR=70% (N=30)
- R/R DLBCL: CAR-T naïve ORR=55% CR=55% (N=11); post-CAR-T ORR=33% CR=21% (N=24)

  - Durable responses (up to 3.5 years so far in FL)
  - Manageable safety profile with CRS observed mainly during cycle 1 step-up dosing
    - 64% of patients experienced treatment-related Grade 3+ AEs

Progress to Date:

- Resumed enrollment in 2Q21, with positive recruitment trends since partial hold was lifted
- Over 450 patients dosed to date across program

Upcoming Milestones:

- Complete enrollment in potentially pivotal Ph2 in FL and DLBCL
- Initiate dosing with subcutaneous formulation
- Initiate OLYMPIA Ph3 program and additional combinations, including TAAxCD28 costim

Efficacy – Early, deep, and durable responses:

- 75% ORR, with 58% VGPR or better at higher doses (200-800 mg)
- 51% ORR among all enrolled patients
- 86% of responders with VGPR or better; 43% with CR or better
- Median DOR was not reached

Safety – Acceptable safety and tolerability:

- No Grade 3+ CRS; no grade 3+ ICANS
- CRS reported in 38% patients, vast majority of events were Gr1
- All patients experienced some grade of TEAEs, with 42% Grade 3 and 33% Grade 4
- Maximum tolerated dose was not reached

Next Steps:

- Complete enrollment in the Ph2 part of the potentially pivotal study
- Report data from Ph2 study
- Start enrollment of Ph1 umbrella study of REGN5458 in combination with SOC
- Initiate additional combinations with TAAxCD28 costim

This slide contains investigational products not yet approved by regulatory authorities

DLBCL, Diffuse Large B Cell Lymphoma; FL, Follicular Lymphoma; ORR, objective response rate; VGPR, very good partial response; CR, complete response; DOR, duration of response; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; SOC, standard of care
Bispecifc ss for Solid Malignancies: Potential to Extend Benefits of Checkpoint Inhibitors; Initial Data in 2022

Our footprint in oncology continues to expand

### Lung, Advanced Cancers
- **REGN5093 (METxMET)**
  - Seeing early signs of clinical activity in **MET exon14 skip** mutation and **MET protein overexpression** patient populations
  - Data anticipated in **2H22**

- **REGN5093-M114 (METxMET ADC)**
  - Trial Enrolling

- **REGN7075 (EGFRxCD28)**
  - Dose escalation in combination with **LIBTAYO** ongoing

### Ovarian Cancer
- **REGN4018 (MUC16xCD3)**
  - Encouraging early signals observed in a heterogeneous ovarian cancer population
  - Data from dose-escalation monotherapy FIH study anticipated in **2022**
  - Dose escalation with **LIBTAYO** ongoing

- **REGN5668 (MUC16xCD28)**
  - Evaluating combinations with **LIBTAYO** or with **MUC16xCD3**

### Prostate Cancer
- **REGN5678 (PSMAxCD28)**
  - Dose escalation with **LIBTAYO** ongoing
  - Initial data expected in **2022**

- **REGN4336 (PSMAxCD3)**
  - Now enrolling
  - Explored in monotherapy and in combination with **LIBTAYO**
### Broad Oncology Pipeline Continues to Advance

**ONGOING**

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Combinations</th>
<th>Disease</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN3767 (LAG-3)</td>
<td>+</td>
<td>LIBTAYO*</td>
<td>Advanced Lung cancer (chemo combo); adjuvant CSCC</td>
</tr>
<tr>
<td>REGN6569 (GITR)</td>
<td>+</td>
<td>LIBTAYO*</td>
<td>Advanced melanoma</td>
</tr>
<tr>
<td>REGN4018 (MUC16xCD3)</td>
<td>+</td>
<td>LIBTAYO*</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>REGN5668 (MUC16xCD28)</td>
<td>+</td>
<td>REGN4018 / LIBTAYO*</td>
<td>2+ line Ovarian cancer</td>
</tr>
<tr>
<td>REGN5678 (PSMAxCD28)</td>
<td>+</td>
<td>LIBTAYO*</td>
<td>3+ line Ovarian cancer</td>
</tr>
<tr>
<td>PSMAXCD3</td>
<td>+</td>
<td>REGN5678/LIBTAYO*</td>
<td>Prostate cancer</td>
</tr>
<tr>
<td>REGN7075 (EGFRxCD28)</td>
<td>+</td>
<td>LIBTAYO*</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>Odonextamab (CD20xCD3)</td>
<td>+</td>
<td>LIBTAYO*</td>
<td>3+ line Lymphoma</td>
</tr>
<tr>
<td>Odonextamab (CD20xCD3)</td>
<td>+/-</td>
<td>LIBTAYO*</td>
<td>3+ line Lymphoma</td>
</tr>
<tr>
<td>REGN5458/9 (BCMAxCD3)</td>
<td>+</td>
<td>LIBTAYO*</td>
<td>3+ line Multiple myeloma</td>
</tr>
<tr>
<td>REGN5093 (METxCD28)</td>
<td>+</td>
<td>B cell/CD28 costim</td>
<td>B-NHL</td>
</tr>
<tr>
<td>REGN5093-M114 (METxCD28)</td>
<td>+</td>
<td>Standard of Care</td>
<td>B-NHL</td>
</tr>
</tbody>
</table>

**UPCOMING**

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Combinations</th>
<th>Disease</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odonextamab (CD20xCD3)</td>
<td>+</td>
<td>Plasma cell/CD28 costim</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>REGN5458/9 (BCMAxCD3)</td>
<td>+</td>
<td>Standard of Care, Additional Combos</td>
<td>Multiple myeloma</td>
</tr>
</tbody>
</table>

*VelocImmune® Antibodies*  
*Anti-PD-1*  
*CD3 BiSpecifics*  
*Costim BiSpecifics*  
*New BiSpecifics*  

*In collaboration with Sanofi  
This slide contains investigational products not yet approved by regulatory authorities*
Regeneron Technologies Power Our Pipeline: TRAPs, Antibodies and Bispecifics

Regeneron technologies have delivered repeated breakthroughs by addressing limitations and bottlenecks in every step of the drug discovery process.
Synergistic Collaborations Supercharge Regeneron’s Future Turnkey Genetics Therapeutics Platforms

Learnings from **mouse genetics**

*VELOCIGENE*®

Unlocking capabilities of **mouse and human genetics** through

*VELOCIGENE*® + RGC

Existing Turnkey Technologies

*Biologics*

- TRAPs
- Antibodies & Bispecifics
- siRNA

Gene editing (insertion/knockout)

Gene Therapy
Regeneron Genetics Medicines

Powerful resource linking human genetic variation to disease; empowering strategic partnerships to drive the future of medicine

Novel Genetics-based Drug Target Discovery

- RGC discovered >10 novel drug targets

Genetics-based Drug Development & Precision Medicine

- RGC database links drug targets with disease impact, enhancing probability of clinical trial success
- RGC database identifies patients most likely to benefit

Leveraging New Turnkey Therapeutic Approaches

- siRNA gene silencing
- Genome editing – Knockout/Insertion
- Targeted viral-based gene delivery and expression

World leading human sequencing

- ~2M human exomes sequenced
- Linked to Electronic Health Records
- 100+ collaborations globally

Regeneron Genetics Center

~2M human exomes sequenced
Linked to Electronic Health Records
100+ collaborations globally
Regeneron is investing in and delivering technologies well beyond antibodies

- 3 genetics medicines programs in the clinic
- 3-5 additional potential targets to advance to IND-enabling studies in next 12 months
- 30+ additional programs in research and candidate selection phase
- 10+ novel genetic targets discovered

Several near-term opportunities emerging from Regeneron Genetics Medicines:

- Reported landmark TTR genome editing data in 2021; data update 1Q’22
- C5 combo program Ph3 initiations (Myasthenia Gravis and PNH)
- HSD17B13 siRNA initial data from NASH patients Mid’22
- APP siRNA Ph1 start for early onset Alzheimer’s
- DB-OTO gene therapy (hearing loss) Ph1/2 start in 2022

### REGENERON GENETICS MEDICINES

Building the Pipeline for the Future

<table>
<thead>
<tr>
<th>Pre-IND</th>
<th>Clinical Development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FACTOR 8 GENE INSERTION</strong>²</td>
<td><strong>POZELIMAB + CEMDISIRAN</strong>¹</td>
</tr>
<tr>
<td>CRISPR/Cas9 + AAV Transgene Insertion</td>
<td>C5 Antibody + C5 siRNA</td>
</tr>
<tr>
<td>• Hemophilia A</td>
<td>• Myastenia Gravis</td>
</tr>
<tr>
<td><strong>PNPLA3</strong>¹</td>
<td>• Paroxysmal Nocturnal Hemoglobinuria</td>
</tr>
<tr>
<td>PNPLA3 siRNA</td>
<td><strong>FACTOR 9 GENE INSERTION</strong>²</td>
</tr>
<tr>
<td>• Nonalcoholic Steatohepatitis</td>
<td>CRISPR/Cas9 + AAV Transgene Insertion</td>
</tr>
<tr>
<td><strong>ALN-APP</strong>¹</td>
<td>• Hemophilia B</td>
</tr>
<tr>
<td>APP siRNA</td>
<td><strong>GAA GENE INSERTION</strong>²</td>
</tr>
<tr>
<td>• Cerebral Amyloid Angiopathy, Alzheimer’s Disease</td>
<td>CRISPR/Cas9 + AAV Transgene Insertion</td>
</tr>
<tr>
<td><strong>DB-OTO</strong>³</td>
<td>• Pompe Disease</td>
</tr>
<tr>
<td>OTOF AA V Dual Vector Gene Therapy</td>
<td><strong>CEMDISIRAN</strong>¹</td>
</tr>
<tr>
<td>• OTOF Related Hearing Loss</td>
<td>C5 siRNA</td>
</tr>
<tr>
<td><strong>NTLA-2001</strong>²</td>
<td>• Immunoglobulin A Nephropathy</td>
</tr>
<tr>
<td>CRISPR/Cas9</td>
<td><strong>ALN-HSD</strong>¹</td>
</tr>
<tr>
<td>GAA GENE INSERTION²</td>
<td>HSD17B13 siRNA</td>
</tr>
<tr>
<td>• Nonalcoholic Steatohepatitis</td>
<td><strong>FACTOR 9 GENE INSERTION</strong>²</td>
</tr>
<tr>
<td>CRISPR/Cas9 + AAV Transgene Insertion</td>
<td><strong>GAA GENE INSERTION</strong>²</td>
</tr>
<tr>
<td>• Pompe Disease</td>
<td>CRISPR/Cas9</td>
</tr>
<tr>
<td><strong>PNPLA3</strong>¹</td>
<td><strong>FACTOR 8 GENE INSERTION</strong>²</td>
</tr>
</tbody>
</table>

### ADDITIONAL PROGRAMS

- 30+ Programs in Research and Candidate Selection

**Collaborations with:**
1. Alnylam Pharmaceuticals
2. Intellia Therapeutics
3. Decibel Therapeutics

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.
Regeneron-Discovered, Approved and Investigational Medicines Across a Wide and Diverse Set of Diseases

### PHASE 1
- fianlimab (LAG-3)
- METxMET (REGN5093)
- METxMET ADC (REGN5093-M114)
- MUC16xCD3 (REGN4018)
- MUC16xCD28 (REGN5668)
- GITR (REGN6569)
- PSMAxCD28 (REGN5678)
- PSMAxCD3 (REGN4336)
- EGFRxCD28 (REGN7075)
- odronextamab (CD20xCD3)
- IL-2Rg (REGN7257)
- TTR (NTLA-2001)
- Factor XI (REGN9933)
- BCMAxCD3 (REGN5459)
- NPR1 (REGN5381)
- HSD17B13 (ALN-HSD)
- IL-36R (REGN6490)

### PHASE 2
- cemiplimab* (PD-1)
- odronextamab (CD20xCD3)
- cemdisiran‡ (C5)
- pozelimab (C5)
- pozelimab + cemdisiran‡ (C5 + C5)
- BCMAxCD3 (REGN5458)
- evinacumab (ANGPTL3)
- LEPR (REGN4461)
- garetosmab (Activin A)
- afiblercept (VEGF)
- sarilumab* (IL-6R)
- dupilumab* (IL-4R)

### PHASE 3
- cemiplimab* (PD-1)
- pozelimab + cemdisiran‡ (C5 + C5)
- alirocumab (PCSK9)
- fasinumab† (NGF)
- casirivimab + imdevimab^ (SARS-CoV-2)
- afiblercept (VEGF)
- dupilumab* (IL-4R)
- itepekimab* (IL-33)
- Bet v 1 (REGN5713-5714-5715)
- Fel d 1 (REGN1908-1909)

### APPROVED
- Over 30 product candidates

---

* In collaboration with Sanofi
† In collaboration with Teva and Mitsubishi Tanabe
^ In collaboration with Roche
‡ In collaboration with Alnylam
# In collaboration with Intellia

This slide contains investigational products not yet approved by regulatory authorities.
## Multiple Potential FDA Submissions: 2022-2024+

<table>
<thead>
<tr>
<th>Year</th>
<th>Product</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>EYLEA</td>
<td>Q16W in NPDR (1H22)</td>
</tr>
<tr>
<td>2022</td>
<td>DUPIXENT*</td>
<td>Eosinophilic Esophagitis (1H22)</td>
</tr>
<tr>
<td>2022</td>
<td>DUPIXENT*</td>
<td>Prurigo Nodularis (1H22)</td>
</tr>
<tr>
<td>2022</td>
<td>DUPIXENT*</td>
<td>Chronic Spontaneous Urticaria (2H22)</td>
</tr>
<tr>
<td>2022</td>
<td>Odrontemab (CD20xCD3)</td>
<td>B Cell NHL (2H22)</td>
</tr>
<tr>
<td>2023</td>
<td>DUPIXENT*</td>
<td>Bullous Pemphigoid</td>
</tr>
<tr>
<td>2023</td>
<td>DUPIXENT*</td>
<td>Chronic Inducible Urticaria - Cold</td>
</tr>
<tr>
<td>2023</td>
<td>Fianlimab (LAG3) + LIBTAYO</td>
<td>Advanced Melanoma</td>
</tr>
<tr>
<td>2023</td>
<td>REGN4461 (LEPR)</td>
<td>Generalized Lipodystrophy</td>
</tr>
<tr>
<td>2023</td>
<td>REGN1908-1909 (Feld1)</td>
<td>Chronic Obstructive Pulmonary Disease</td>
</tr>
<tr>
<td>2023</td>
<td>REGN5713-5714-5715 (Betv1)</td>
<td>Birch Allergy</td>
</tr>
<tr>
<td>2023</td>
<td>Pozelimab ± cemdisiran*</td>
<td>C5-mediated diseases</td>
</tr>
<tr>
<td>2024+</td>
<td>Garetosmab</td>
<td>FOP^</td>
</tr>
<tr>
<td>2022</td>
<td>Aflibercept 8mg</td>
<td>Wet AMD/DME (2H22/1H23)</td>
</tr>
<tr>
<td>2024+</td>
<td>REGN5458 (BCMAxCD3)</td>
<td>R/R Multiple Myeloma (2H22/1H23)</td>
</tr>
</tbody>
</table>

* Partial clinical hold pending review of additional data
NPDR – Non-Proliferative Diabetic Retinopathy
FOP – Fibrodysplasia Ossificans Progressive

* In collaboration with Sanofi
+ In collaboration with Alnylam
This slide contains investigational products not yet approved by regulatory authorities
Key Upcoming Milestones (Next 12 Months)

**EYLEA**
- Ph3 data readout for Aflibercept 8mg formulation

**Dupixent**
- Complete regulatory submission for EoE and PN
- Additional Phase 3 data readouts for CSU
- Regulatory decision for AD in children (6mo–5yrs)

**REGEN-COV**
- FDA decision on BLA for treatment and prophylaxis indications (PDUFA 4/13/22)
- Advancement of next-generation candidate to the clinic

**Libtayo**
- Regulatory decisions for 1L NSCLC chemotherapy combination (PDUFA 9/19/2022)

**Solid Tumor Bispecifics**
- Initial data for MUC16xCD3, PSMAxCD28 and METxMET

**Odronextamab (CD20xCD3)**
- Complete enrollment in potentially pivotal Phase 2 in NHL
- Initiate dosing with subcutaneous formulation
- Initiate OLYMPIA Ph3 program and additional combinations

**REGN5458 (BCMAxCD3)**
- Complete enrollment in potentially pivotal Phase 2 in multiple myeloma
- Ph2 data expected in multiple myeloma
- Initiate studies with subcutaneous formulation
- Initiate Phase 1 and Phase 3 studies exploring combinations with standard of care
- Initiate additional combination studies
Strong Financial Position Enabling Critical Investments

Capital allocation priorities reflect business priorities

1. **Invest** in our best-in-class R&D capabilities

2. **Pursue** and fund business development opportunities to enable and synergize our R&D capabilities and technologies

3. **Return** cash to shareholders through share repurchases

$1.8B investment in Tarrytown R&D facilities
Continued investments in manufacturing capacity

Productive collaborations with Alnylam and Intellia
Signed new agreement with Nykode in 4Q21

Over $7.8B in share repurchases since November 2019*
Announced $3B share repurchase authorization in November 2021

* As of December 31, 2021
## Reconciliation of Total Revenue excluding REGEN-COV (casirivimab and imdevimab)

<table>
<thead>
<tr>
<th>Revenue reconciliation:</th>
<th>Three Months Ended December 31,</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021</td>
<td>2020</td>
</tr>
<tr>
<td>Total revenues</td>
<td>$4,951.7</td>
<td>$2,422.9</td>
</tr>
<tr>
<td>REGEN-COV net product sales in the United States</td>
<td>2,297.9</td>
<td>145.5</td>
</tr>
<tr>
<td>Global gross profit true-up payment from Roche in connection with sales of casirivimab and imdevimab</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Total revenues excluding REGEN-COV (casirivimab and imdevimab)</td>
<td>$2,653.8</td>
<td>$2,277.4</td>
</tr>
</tbody>
</table>

See slide 2 for additional important information regarding non-GAAP financial measures included in this presentation.